Online Registry for Patent Ductus Arteriosus in Very Preterm Infants in Shenzhen: Protocol for a Multicenter, Prospective, Observational Cohort Study

Every year, thousands of babies are born too early, arriving in the world before their bodies have finished their final, crucial preparations. Among the most vulnerable are those born before 32 weeks of gestation or weighing less than 1,500 grams. For these tiny infants, the transition from the womb to the outside world is fraught with challenges, one of which is a common heart condition known as a patent ductus arteriosus. In a developing fetus, a small blood vessel called the ductus arteriosus acts as a necessary shortcut, allowing blood to bypass the lungs, which are not yet in use. Normally, this vessel closes shortly after birth as the baby begins to breathe. However, in many very preterm infants, it remains open. When this happens, blood flows backward from the body into the lungs, a situation that can overwhelm the delicate lungs, strain the heart, and increase the risk of serious complications like bleeding in the brain or damage to the intestines. While doctors have long known that this condition is dangerous, they have struggled to agree on exactly which babies are at the highest risk or the best time to intervene, largely because high-quality data from large groups of patients has been missing.

To address this gap, a team of researchers in Shenzhen, China, is launching a major new effort to track these infants systematically. Rather than looking back at old records, which often miss important details, they are building a forward-looking study that follows babies from the moment they are born. The project, titled the Online Registry for Patent Ductus Arteriosus in Very Preterm Infants, brings together four top-tier hospitals in the city to create a single, unified database. Over a three-year period, starting in early 2026, the team plans to enroll more than 300 very preterm infants who have been confirmed to have this open heart vessel. By using a secure, cloud-based platform, doctors at each hospital will enter standardized information about the babies' health, their heart scans, and the treatments they receive. This approach ensures that the data is consistent and reliable, allowing the researchers to see patterns that might be invisible in smaller, isolated studies.

The primary goal of this study is to create a tool that can predict which babies are most likely to develop a severe form of the condition, known as haemodynamically significant patent ductus arteriosus. This specific type is dangerous because the blood flow is strong enough to cause immediate harm. The researchers will gather a wide range of information, including the baby's size, the mother's health during pregnancy, and detailed measurements from ultrasound images of the heart. They will then use advanced computer methods to analyze this data and build a model that can identify high-risk infants early in their hospital stay. If successful, this model could help doctors decide who needs immediate treatment and who can be watched more closely, potentially preventing serious complications before they start. The study also aims to understand how this condition affects a child's development in the long run, with plans to follow the children until they are about two years old to check their growth and neurological health.

Beyond just tracking numbers, the researchers are also collecting biological samples, such as small amounts of blood, stool, and urine, as well as breast milk from the mothers. These samples will be stored in a dedicated biobank, creating a resource for future scientists to study the biological mechanisms behind why some babies develop this condition while others do not. To ensure the findings are robust, the study will also include a comparison group of very preterm infants who do not have the open vessel, matched carefully by age and weight, to see how their outcomes differ. The team acknowledges that this is an observational study, meaning they are watching what happens naturally rather than testing a specific treatment, so they cannot prove that one medicine is better than another. However, by providing a clear, detailed picture of how the condition behaves in a real-world setting, the study aims to lay the groundwork for better guidelines and more effective care.

The researchers recognize that their work has limits, particularly because it is focused on one city and may not perfectly reflect conditions in other parts of the world or among different populations. They also note that following children for only two years might not reveal problems that appear later in life. Despite these constraints, the establishment of this dedicated online registry represents a significant step forward for neonatal medicine in China. It moves the field away from scattered, retrospective reviews and toward a coordinated, prospective approach where data is collected with precision and purpose. By combining clinical observations with biological samples and long-term follow-up, the study seeks to transform how doctors understand and manage this common but complex heart condition, ultimately working toward a future where the most vulnerable preterm infants receive the right care at the right time.